Comprehensive Evidence-Based Neuropathy Treatment Program: Regenerative and Non-Surgical Approaches

A Practical Guide to Non-Pharmacologic, Integrative Care

Last updated: February 26, 2026

By: BRADLEY MOUROUX, D.C. CCSP

Campbell Clinic (Santa Clara County / San Jose) Spine & Injury Center of San Jose 420 Marathon Drive, Campbell, CA 95008
Phone: (408) 379-8888

Danville Clinic (San Ramon Valley / East Bay) Sycamore Valley Chiropractic 401 Sycamore Valley Road West, Danville, CA 94526
Phone: (925) 837-5595

Table of Contents

Key Terms (for search)

- peripheral neuropathy
- diabetic peripheral neuropathy
- chemotherapy-induced peripheral neuropathy
- neuropathic pain
- photobiomodulation
- red light therapy
- infrared therapy
- shockwave therapy
- TENS
- PEMF
- H-Wave
- vibration therapy
- alpha-lipoic acid
- benfotiamine
- omega-3
- methylcobalamin
- spinal decompression
- chiropractic care

Guide

Introduction

Peripheral neuropathy is a widespread neurological condition marked by damage to peripheral nerves, leading to numbness, tingling, burning sensations, weakness and impaired balance (Joshua, 2022). U.S. population studies, peripheral neuropathy affects approximately 10.4 % of middle-aged adults (aged 40-69), rising to 26.8 % among those aged 70 and older and reaching 34.2 %-42.4 % in individuals aged 80 and above (Hicks et al., 2021). About 13.5 % of adults aged 40 and older are affected (Hicks et al., 2021). Globally, prevalence estimates are lower; about 2.4 % of the population experiences peripheral nerve disorders with rates of approximately 8 % in older age groups (Hammi, 2022). When focusing on neuropathic pain, prevalence in the general population ranges from 7 % to 10 %, increasing to 20 %-30 % in people with diabetes (Baskozos et al., 2023). Disorders of the peripheral nervous system including polyneuropathy that account for approximately 10 % of all neurology visits globally each year (Elafros et al., 2022; Foundation for Peripheral Neuropathy, 2022). In the United States, direct annual healthcare costs for diabetic polyneuropathy are estimated at nearly $11 billion (Foundation for Peripheral Neuropathy, 2022) Current drug-based treatments, such as gabapentin, pregabalin and duloxetine which target symptom relief rather than nerve repair which may cause dizziness, sedation, gastrointestinal upset and reduced adherence which highlights the demand for safer alternatives. Increasing evidence supports non-pharmacological, integrative approaches including photobiomodulation, extracorporeal shock wave therapy, electrical stimulation, vibration therapy, nutritional supplementation and chiropractic care which focus on nerve regeneration, improved circulation and functional recovery. Randomized controlled trials demonstrate measurable benefits; for example, infrared light therapy shows up to 66% improvement in pain and sensation scores, while shock wave therapy improves nerve conduction and reduces pain scores significantly over 12-week treatment courses. Electrical stimulation therapies, including transcutaneous electrical nerve stimulation (TENS) and pulsed electromagnetic field (PEMF) therapy, have demonstrated efficacy in reducing neuropathic pain. A meta-analysis of TENS interventions reported a standardized mean difference (SMD) of −1.58, indicating a significant reduction in pain intensity compared to sham treatments (Johnson et al., 2022). Studies on PEMF therapy have shown promising results with one study reporting a 41.6% decrease in visual analog scale (VAS) pain scores among cancer patients. Given the increasing prevalence of neuropathy, escalating healthcare costs and the limited efficacy of pharmacological treatments, both patients and clinicians are increasingly adopting integrative, evidence-based strategies. These approaches combine established therapies like TENS and PEMF with emerging modalities to enhance long-term outcomes and improve quality of life (Wang et al., 2024).

Understanding Peripheral Neuropathy: Causes and Symptoms

Peripheral neuropathy reflects failure of peripheral axons and Schwann cells from metabolic, vascular, toxic or immune causes. At the molecular level persistent hyperglycemia redirects glucose through the polyol pathway causing sorbitol accumulation, NADPH depletion and oxidative stress that disrupt axonal transport and mitochondrial function. Advanced glycation end products modify proteins and activate RAGE and NF-kB signaling which sustains neuroinflammation and injures microvascular endothelium, reducing perfusion to nerves. Mitochondrial dysfunction and impaired mitophagy produce ATP deficit and excess reactive oxygen species which compromise distal axonal maintenance and slow axonal transport of mitochondria and neurotrophic factors. Inflammatory cytokines recruit macrophages and activate Schwann cells toward maladaptive phenotypes that promote demyelination and secondary axonal loss. Chemotherapy agents damage peripheral neurons through distinct molecular mechanisms. Taxanes stabilize microtubules and block axonal

transport. Platinum compounds induce DNA adducts in dorsal root ganglia and disrupt mitochondrial bioenergetics. These insults alter ion channel expression including NaV and TRP families producing ectopic firing, allodynia and burning paresthesia. Small fiber neuropathy selectively targets thin unmyelinated C fibers and small myelinated Aδ fibers and presents early as burning pain, thermal dysesthesia and autonomic dysfunction while large fiber involvement yields numbness, proprioceptive loss and gait instability. Injury related neuropathy from compression or trauma produces focal Wallerian degeneration. Idiopathic neuropathy likely reflects mixed metabolic, genetic and immune contributions that require targeted evaluation. Clinically early intervention is critical because progressive axonal loss predicts persistent disability. Detecting small fiber loss, correcting metabolic drivers, reducing toxic exposures and initiating neuroprotective or neuroregenerative therapies early offer the best chance to preserve fibers, restore conduction and reduce long term morbidity. (Laforgia et al., 2021; Li et al., 2024; Saleh & Sedik, 2024).

Infrared and Red Light Therapy for Neuropathy: Evidence and Benefits

Photobiomodulation, also called low level laser therapy or red and near-infrared light therapy, supports nerve recovery by acting on mitochondrial chromophores, notably cytochrome c oxidase, which increases ATP production, transiently modulates reactive oxygen species, releases nitric oxide and upregulates growth and angiogenic signals such as NGF and BDNF; these molecular effects reduce neuroinflammation, improve microvascular perfusion and restore axonal transport mechanisms repeatedly described in mechanistic reviews (Dompe et al., 2020). Clinical evidence from randomized trials and systematic reviews is consistent but heterogeneous. A sham-controlled trial in chemotherapy-induced peripheral neuropathy (70 patients) reported large, clinically meaningful reductions in modified Total Neuropathy Score with photobiomodulation versus sham at 4, 8 and 16 weeks (mTNS fell ~32% at 4 weeks and >50% at 8 weeks in the active arm). (Argenta et al., 2016) A 2023 randomized study in diabetic peripheral neuropathy (60 patients) using 630 nm and 810 nm, 15-minute sessions three times weekly for 12 sessions, improved monofilament detection and Michigan Neuropathy Screening Instrument scores without adverse events (Ebadi et al., 2023).Systematic reviews and focused meta-analyses summarize eight to twenty controlled studies showing improvement in neuropathic pain and nerve conduction velocity, while noting wide variability in wavelength, dose, irradiance and session number (Korada et al., 2022). Pragmatic treatment parameters used in trials range from 15 to 30 minutes per session, three times weekly, over 4 to 12 weeks, using visible red (around 630 nm) up to near-infrared (800-900 nm) devices. Reported safety is excellent in trials with negligible adverse effects (Ebadi et al., 2023). For patients the takeaways are precise: photobiomodulation offers a noninvasive option with plausible molecular rationale and level-II evidence of benefit, but effectiveness depends on correct wavelength, dose and clinical delivery. Home devices vary widely and have limited high-quality outcome data. Until standardized dosing and long-term trials are available clinicians should prefer clinic-grade, parameter-documented protocols or use home devices only under clinical guidance (De Oliveira Rosso et al., 2018).

Shockwave Therapy for Nerve Regeneration and Pain Relief

Extracorporeal shock wave therapy applies focused or radial acoustic pulses that mechanically stimulate tissue to trigger angiogenesis, growth factor release, stem cell recruitment and anti-inflammatory signaling, mechanisms that together foster axonal sprouting, remyelination and improved microvascular perfusion necessary for nerve repair (Guo et al., 2022) (Kou et al., 2024). Animal models show protection against diabetes-induced nerve degeneration, preservation of axons and recovery of motor and sensory function after ESWT (Chen et al., 2015). Clinical data are promising but heterogeneous. Systematic reviews and meta-analyses report consistent reductions

in pain and functional gains across peripheral nerve and musculoskeletal indications with one review finding an average visual analogue scale reduction of about 1.49 points versus controls in randomized trials (De La Corte-Rodríguez et al., 2023). Recent neuropathy-focused reviews and a 2024 meta-analysis identified statistically significant improvements in pain, some electrodiagnostic parameters and reductions in nerve cross-sectional area but effect sizes and study quality vary and follow-up durations are short (Yang et al., 2024). Typical clinical protocols reported in the literature use low to medium energy flux densities, commonly 0.08 to 0.28 mJ/mm2 and 1,500 to 3,000 impulses per session, delivered in one to five sessions spaced days to weeks apart. The International Society for Medical Shockwave Treatment recommends tailoring energy and session number to device type and patient tolerance and notes transient local bruising, petechiae, or short-lived pain as the principal adverse events (International Society for Medical Shockwave Treatment., 2024). Key measurable outcomes observed in trials include clinically meaningful pain score reductions, improved monofilament or sensory testing in diabetic cohorts, shortened distal latency or increased sensory nerve action potential in some studies and decreased nerve cross-sectional area on ultrasound in others ("Effect of Extracorporeal Shockwaves on Diabetic Neuropathic Foot," 2020) (Jeong et al., 2023). At present ESWT for peripheral neuropathy should be regarded as a promising, mechanistically plausible therapy supported by moderate-quality evidence. Larger, parameter-standardized randomized trials with longer follow-up are required before ESWT can be considered established for routine neuropathy care (Yang et al., 2024) (International Society for Medical Shockwave Treatment, 2024).

Electrical Nerve Stimulation: TENS, PEMF and H-Wave Devices

Electrical nerve stimulation encompasses several distinct technologies that relieve neuropathic pain and may aid recovery by modulating neuronal excitability, increasing local blood flow and promoting neurotrophic signaling. TENS delivers pulsed current through skin electrodes to activate large diameter afferents and reduce pain via gate control and descending inhibition. High quality systematic reviews conclude TENS produces modest but real short term pain relief versus placebo with moderate certainty for immediate effects and no serious safety concerns (Johnson et al., 2022). Pulsed electromagnetic field therapy (PEMF) uses time-varying magnetic fields to alter membrane potentials, improve microvascular perfusion and potentially stimulate small fiber repair; recent pilot and randomized studies in diabetic symmetric peripheral neuropathy report improved skin perfusion pressure and pain scores, though samples remain small and protocols vary (Tassone et al., 2023). H-Wave is a proprietary waveform designed to produce non-fatiguing muscle contractions, enhance lymphatic and microvascular flow and reduce chronic pain. A focused review and several clinical reports show favorable pain and function outcomes, but many studies are small or industry supported and lack long follow up (Williamson et al., 2021) (Blum et al., 2008). Comparative data are limited. Direct comparisons in neuropathic or post-herpetic pain suggest TENS and PEMF can be similarly effective for short term pain reduction, while H-Wave aims to provide longer term functional gains through circulatory effects. One network of trials and secondary analyses reports a pooled mean pain intensity reduction of roughly -1.6 points on standard scales for electrical stimulation versus sham in mixed neuropathic conditions, but heterogeneity in devices, dose and outcome timing weakens certainty (Johnson et al., 2022). Clinically important points for practice are clear. TENS is inexpensive, widely available and suitable for home use with clinician instruction. PEMF and H-Wave generally require clinic delivery or validated prescription devices to ensure correct parameters. Adverse events are rare and usually limited to transient skin irritation or local discomfort. Because efficacy hinges on waveform, frequency, intensity, session length and placement, clinicians should document device parameters and use sham-controlled evidence where available when recommending a modality. Current evidence supports electrical stimulation as a safe adjunct that provides meaningful pain relief for

many patients, but larger, parameter-standardized randomized trials with longer follow up are needed to define comparative effectiveness and optimal treatment regimens (Wolfe et al., 2024) (Vance et al., 2022).

Vibration Therapy and Sensory Stimulation

Vibration therapy and targeted sensory stimulation modify peripheral afferent input to improve circulation, proprioception and pain modulation through mechanotransduction, enhanced microvascular perfusion and reflexive increases in muscle spindle and cutaneous receptor activity. Whole-body vibration (WBV) and local plantar or focal vibration amplify sensory feedback, lower vibration perception thresholds and improve balance and gait by restoring sensory weighting in postural control circuits, while low-intensity vibration appears to support microvascular flow and neurotrophic signaling that can protect small fibers. Controlled trials and systematic reviews report consistent short-term gains in pain, balance and sensory thresholds in diabetic peripheral neuropathy with randomized studies showing pain reduction and improved neuropathy disability scores after multiweek WBV programs (Jamal et al., 2019) (Robinson et al., 2018). Local plantar vibration trials demonstrate improved protective sensation and postural stability and have reduced pain in small RCTs and feasibility studies, suggesting focal vibration may be particularly useful for distal, length-dependent neuropathies (Sabziparvar et al., 2022). Evidence for chemotherapy induced peripheral neuropathy is emerging but limited; pilot trials of low-intensity vibration indicate feasibility and possible symptom benefit yet larger randomized trials are needed to confirm durability (Krasnow et al., 2025) (Sohrabzadeh et al., 2021). Effect sizes vary by protocol. Several sham-controlled WBV trials reported clinically meaningful pain decreases within weeks and retained benefit beyond the day of treatment in some cohorts, but other preclinical and clinical studies show no structural regeneration on morphometry, exposing heterogeneity in dosing and outcomes (Kessler et al., 2020) (De Oliveira Marques et al., 2021). Practical guidance is straightforward. Patients with diabetic, age-related,or length-dependent neuropathy who have impaired balance, reduced foot sensation or chronic distal pain are most likely to benefit from supervised WBV or focal plantar vibration combined with balance and strength training. Contraindications include recent thromboembolism, unstable cardiovascular disease and acute fracture. Adverse effects are uncommon and usually transient, consisting of local discomfort, dizziness or mild musculoskeletal soreness. Clinicians should prioritize protocols validated in RCTs, document vibration frequency, amplitude, session duration and cumulative dose and couple vibration with exercise and metabolic optimisation to maximise functional gains while awaiting larger, parameter-standardized trials.

Nutritional Supplements for Nerve Health

Nutritional supplementation plays a central role in strategies for protecting peripheral nerve function in conditions such as diabetic, idiopathic and chemotherapy-induced neuropathy (Liu., 2020). Benfotiamine, a lipid-soluble thiamine derivative, bypasses active transport limitations of thiamine and enhances transketolase activity, diverting glucose metabolites away from pathways that promote vascular and neural injury, including the hexosamine and advanced glycation end-product cascades (Beltramo., 2008). Mechanistic reviews confirm these molecular benefits but a 24-month randomized trial at 300 mg per day failed to show significant changes in nerve function or inflammation markers, suggesting its use may be most effective for symptom management in the short term Short-term human studies, ranging from three to twelve weeks, indicate that high doses of benfotiamine up to 600 mg daily may improve symptom scores in diabetic polyneuropathy (Fraser., 2012). Clinical studies using 300 mg twice daily over several weeks have reported improvement in neuropathic symptoms without notable adverse effects. Omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exhibit neuroprotective effects

through anti-inflammatory signaling and support for myelin repairA randomized, double-blind, placebo-controlled trial by Ghoreishi et al. (2012) assessed the efficacy of omega-3 fatty acids in reducing paclitaxel-induced peripheral neuropathy (PIPN) in breast cancer patients. Participants receiving 640 mg of omega-3 fatty acids three times daily during chemotherapy and for one month after treatment experienced a significant reduction in neuropathy incidence. About 70% of the omega-3 group did not develop peripheral neuropathy, compared to 40.7% in the placebo group, yielding an odds ratio of 0.3 (95% CI: 0.10-0.88, p = 0.029) .

A systematic review and meta-analysis by Zhang et al. (2019) examined the effects of omega-3 polyunsaturated fatty acid supplementation on peripheral neuropathy. The pooled data indicated a reduced incidence of peripheral neuropathy with a relative risk of 0.58 (95% CI: 0.43-0.77), suggesting a protective effect of omega-3 supplementation against chemotherapy-induced peripheral neuropathy (Zhang et al., 2019). Trials in type 1 diabetes have demonstrated measurable improvement in corneal nerve fiber metrics, a validated biomarker of early small fiber neuropathy. These studies, along with FDA approval of daily intake up to 3 g of combined EPA and DHA, support the integration of omega-3 supplementation as a clinically meaningful preventive and restorative measure for neuropathy. Alpha-lipoic acid (ALA), a potent antioxidant and mitochondrial cofactor, has demonstrated consistent benefit in trials such as SYDNEY-2 and NATHAN 1, where daily dosing of 600 to 1,200 mg improved neuropathy symptom scores and nerve blood flow over months to years (Ziegler, 2023; Ziegler et al., 2006; Abdullah et al., 2024).

Though generally safe, higher doses may produce gastrointestinal discomfort. B-complex vitamins, including thiamine, pyridoxine, folate and cobalamin, are foundational for nerve metabolism and myelin synthesis and excessive pyridoxine intake above 50 mg daily is associated with sensory neuropathy and dosing should remain within evidence-based limits (Health Sciences Authority, 2023; Therapeutic Goods Administration, 2022). Magnesium is critical for nerve conduction and synaptic stability, is widely recommended to correct deficiency while neuropathy-specific data are limited. Diet and lifestyle interventions amplify the effects of supplementation; strict glycemic control, anti-inflammatory dietary patterns rich in omega-3 fatty acids and structured strength and balance training enhance microvascular health and neuronal resilience. Together, these interventions form a comprehensive approach where benfotiamine offers targeted glucose metabolism support, omega-3 fatty acids improve conduction and reduce inflammatory damage, ALA mitigates oxidative stress and B vitamins maintain metabolic integrity. Current evidence supports their inclusion in neuropathy treatment protocols, but long-term benefit depends on early diagnosis, critical metabolic management and combination with physical and rehabilitative therapies. Supplements should be selected and dosed under clinical guidance with close monitoring to ensure efficacy and safety (Health Sciences Authority, 2023).

Chiropractic Care for Improved Movement and Body Mechanics in Neuropathy

Chiropractic care focuses on optimizing joint mobility, spinal function, and overall biomechanics to address secondary effects of peripheral neuropathy, such as impaired balance, gait abnormalities, and compensatory pain. By restoring proper movement and alignment, chiropractic adjustments aim to enhance proprioceptive feedback, reduce mechanical stress on the body, and improve circulation, all of which create a better environment for nerve function and support a patient's ability to engage in rehabilitative exercise.

Restricted spinal or extremity joint motion can alter sensory input to the central nervous system, negatively affecting motor control and coordination. Manual therapies, including spinal manipulation and mobilization, work to normalize this input. Improved joint mechanics and reduced pain can lead to better movement patterns, increased stability, and a reduced risk of falls, a critical concern for neuropathy patients.

While robust clinical trials specifically on chiropractic and neuropathy are limited, the rationale is supported by its documented effects on sensorimotor function. Case reports illustrate notable functional improvements where a chiropractic approach was part of a broader plan. In one example, a patient with severe foot burning and numbness underwent a 12-week program combining chiropractic adjustments (focused on improving lumbar and lower extremity mobility), infrared therapy, electrical stimulation, and posture exercises. This multimodal approach resulted in dramatically reduced pain, improved walking, and decreased medication reliance (Chiropractic, 2025). Another case documented similar success by integrating spinal care with lifestyle coaching (Advantage Health Center, 2025).

Chiropractic care is inherently integrative, often working alongside physical therapy and rehabilitation. By addressing joint dysfunctions that may hinder exercise, chiropractic can help patients better tolerate and benefit from the sensory-motor training, strength work, and balance activities that are essential for stimulating nerves and improving functional outcomes (Comparative Efficacy of Chiropractic Adjustments in Peripheral Neuropathy Management, n.d.).

Vertebral Axial Decompression: Evidence, Use Cases, and Safety

Vertebral Axial Decompression (VAX-D) Therapy in Neuropathy
Vertebral Axial Decompression (VAX-D) is a non-surgical spinal traction method employing computer-controlled, gradual pull on the lumbar spine to reduce intradiscal pressure. This process is generally referred to as “Non-Surgical Spinal Decompression” or shortened to “Decompression Therapy” in the chiropractic medical field. It was found In one invasive physiological study, intradiscal pressure fell to below -100 mm Hg when tension was applied using a VAX-D table in an L4-L5 disc measurement scenario, indicating effective decompression of the nucleus pulposus (Ramos et al., 1994).

An outcomes study across 778 patients with chronic low back pain, often accompanied by radicular symptoms or degenerative disc conditions, found that 71 % of cases achieved a successful outcome defined as pain reduction to a score of 0 or 1 on a 0-5 scale after at least ten VAX-D sessions (Gose et al., 1998). A similarly structured randomised controlled trial compared VAX-D versus TENS in patients with chronic low back pain and leg pain: 68.4 % of VAX-D patients met a pain reduction criterion (≥ 50 %) versus none in the TENS group ($p < .001$) (Naguszewski et al., 2001)

Physiological measures further support decompression. Using dermatomal somatosensory evoked potentials, researchers demonstrated lumbar nerve root decompression in seven patients with L5-S1 radiculopathy; 100 % reported at least 50 % symptom improvement, with average pain reduction of 77 % (Naguszewski et al., 2001).

However, critical data surfaces caution. A Mayo Clinic-reported case found that VAX-D triggered sudden enlargement of a lumbar disc protrusion after repeated sessions, escalating radicular pain and necessitating urgent microdiskectomy (McMillin & Sherry, 2002). Coverage policies by CMS and insurers reflect this uncertainty. Despite one RCT showing efficacy over TENS, they note methodological limitations, lack of blinding, limited generalizability and urge more rigorous testing (Aetna Clinical Policy Bulletins, 2025). This is despite the presentation of favorable findings in the same bulletin noting a study by Beatti et al 2008 that conducted the administration of a prone lumbar traction protocol. A total of 296 subjects with low LBP and evidence of a degenerative and/or herniated intervertebral disk at 1 or more levels of the lumbar spine were included. The results after 180 day post treatment (81.4 %) subjects researchers noted significant improvements for all post-intervention outcome scores when compared with pre-intervention scores (Beatti et al 2008).

Combined Therapy Approaches: Creating a Personalized Neuropathy Plan

Multimodal therapy addresses neuropathy more effectively than single methods because it confronts multiple pathological processes simultaneously oxidative stress, impaired metabolism, inflammation, mechanical compression and altered nerve signaling. Evidence supports that combining antioxidant or lifestyle interventions with standard care improves outcomes. In one observational prospective study of diabetic neuropathy, combining glycemic control and lifestyle changes with antioxidant supplements increased response rates (decrease in Michigan Neuropathy Screening Instrument scores) from 34% to nearly 39% at one year (Rotaru et al., 2020).

Beyond supplements, clinical consensus and reviews emphasize that therapies combining pharmacologic and non-drug modalities outperform monotherapy. Reviews of neuropathic pain treatments note that combinations of gabapentin or pregabalin with other agents (e.g., COX-2 inhibitors) or the use of high-concentration topical agents with systemic treatments, yield better pain control and fewer side effects than each alone (Vorobeychik et al., 2011). While fewer trials combine non-drug devices, the rationale stands: modalities like photobiomodulation, ESWT, electrical stimulation and nutritional support each affect different mechanisms and can be combined safely, increasing overall efficacy.

Case-based integration embodies this philosophy. In the chiropractic case described, spinal alignment, infrared light therapy, electrical nerve stimulation, supplements and lifestyle coaching coalesced to produce dramatic relief where standard treatments had failed (Chiropractic, 2025). Although anecdotal, such examples show how targeted combinations restore function, reduce symptoms and build patient trust.

To develop personalized plans, clinicians assess each patient's neuropathy subtype, symptom severity, comorbidities and response to initial interventions. They then layer therapies starting with core interventions like glycemic control or spinal decompression, followed by photobiomodulation, ESWT, stimulation devices and vetted supplements as needed. Case narratives help illustrate how that stacking approach can transform outcomes, offering both clinical credibility and empathic engagement.

FAQs: Neuropathy Treatment Without Medications

Is laser therapy FDA-approved for neuropathy?

Low-level laser therapy (LLLT) and photobiomodulation are FDA-cleared for circulation and pain, not specifically neuropathy reversal. RCTs show benefits in pain, sensation and nerve conduction and clinicians may use them “off-label” when evidence supports it.

How long does shockwave therapy take to work?

Extracorporeal shock wave therapy (ESWT) typically requires 1–5 weekly/biweekly sessions. Pain improves in 4–6 weeks with early sensory gains after three sessions; full effects can take 12–16 weeks.

Are electrical stimulation therapies effective?

TENS, PEMF and H-Wave stimulation reduce neuropathic pain. TENS provides short-term analgesia, PEMF enhances microcirculation and H-Wave supports lymphatic/vascular function. Correct protocols are crucial.

Can supplements replace medication?

Alpha-lipoic acid, omega-3s and benfotiamine improve symptoms and offer neuroprotection but do not replace drugs for severe or progressive neuropathy. ALA reduces symptoms by 24–32%; omega-3s may halve chemotherapy-induced neuropathy incidence.

Is chiropractic care safe for neuropathy?

Spinal adjustments and decompression are safe when performed by trained practitioners and may improve circulation, mobility and sensory function. Avoid in severe osteoporosis, spinal instability or advanced spondylosis.

Which therapy has the strongest evidence?

Alpha-lipoic acid and photobiomodulation have the most robust RCT support. ESWT, PEMF and vibration therapy show promising but smaller-scale evidence. Multimodal approaches yield the best long-term outcomes.

Conclusion

Neuropathy management has advanced beyond symptomatic drug therapy with growing evidence for noninvasive interventions that target underlying mechanisms of nerve damage. Photobiomodulation, extracorporeal shockwave therapy, electrical stimulation, vibration-based sensory retraining and carefully selected nutritional supplements demonstrate measurable improvements in pain, sensation and nerve conduction, especially in diabetic and chemotherapy-induced neuropathy. Chiropractic care and physical rehabilitation further enhance circulation, improve sensorimotor function, and optimize body mechanics to support nerve health and functional capacity. Early treatment remains critical, as progressive axonal degeneration limits recovery potential. Patients benefit most when therapies are tailored to individual needs, monitored by clinicians and integrated with metabolic control and lifestyle interventions. This evidence-based, nonpharmacological approach emphasizes neuroprotection, regeneration and functional restoration, offering a realistic path toward improved quality of life and, in many cases, partial nerve recovery.

Neuropathy Treatment Protocol

General guideline ranges used in Dr. Bradley Mouroux's clinic. Parameters may vary by patient presentation, tolerance, and response.

Shockwave (Softshock / StemWave)

Extracorporeal shockwave therapy (ESWT) parameters should be individualized to patient tolerance and device type.

Parameter	Typical range / notes
Setting	Outpatient (in-office care)
Energy range	30-250 mJ*
Pulses per session	500-2,500
Frequency	2-12 pulses/second
Sessions per week	1-2
Total duration	Typically 6-12 weeks* (varies)

Photobiomodulation - Class IV Laser (in-office)

Parameter	Typical range / notes
Wavelength(s)	650, 810, 915, 980, 1064 nm
Power / power density	32-62 W (device dependent)
Session length	3-8 minutes
Frequency	1-3 times/week
Total duration	Typically 12-56 weeks* (varies)

Photobiomodulation - LED infrared pads (home or in-office)

Home devices vary widely by irradiance and total delivered dose. Use clinician guidance for selection and dosing.

Parameter	Typical range / notes
Wavelength(s)	640-660 nm and 840-880 nm
Session length	15 minutes
Frequency	3-7 times/week
Total duration	Indefinite / maintenance

Electrical stimulation

Electrical stimulation includes multiple device categories. Settings and electrode placement should follow manufacturer guidance and clinician instruction.

TENS (home use)

Parameter	Typical range / notes
Session length	15-30 minutes
Frequency	Daily or as needed
Typical frequency range	1-10 Hz or 75-150 Hz (varies by protocol)
Duration of care	Ongoing, as needed

Peripheral nerve stimulation (in-office)

Parameter	Typical range / notes
Frequency	1-2 Hz
Pulse width	0.1-0.2 ms
Current	1-30 mA (patient dependent)
Session length	5-10 minutes
Frequency of visits	2-3 times/week as directed
Duration of care	Variable, up to 12-56 weeks

Electroanalgesic matrix therapy (in-office)

Parameter	Typical range / notes
Frequency range	8,300-10,000 Hz and 0.1-250 Hz
Power	Patient dependent
Session length	20 minutes
Frequency of visits	1-3 times/week as directed
Duration of care	Variable, up to 12-56 weeks

Spinal decompression (for spinal-complication neuropathy)

Parameter	Typical range / notes
Setting	Outpatient (in-office care)
Device type	DRX 9000, AccuSpina, or DOC decompression tables
Region treated	Cervical and/or lumbar spine
Session length	~30 minutes
Frequency	2-3 times/week
Typical total sessions	24*
Common indications	Spinal arthritis, degenerative disc disease, disc herniation/bulge, pinched nerve, sciatica, radiculopathy

Vibration therapy

Focal vibration (home adjunct)

Parameter	Typical range / notes
Device / type	Nerve plate
Frequency	100 Hz+ (Pacinian corpuscle stimulation)
Duration per session	30 minutes
Weekly frequency	7 times/week

Whole-body vibration (in-office or home)

Parameter	Typical range / notes

Device / type	Power Plate
Frequency	20-30 Hz (Meissner corpuscle stimulation)
Duration per session	5-10 minutes
Weekly frequency	2-3 times/week

Chiropractic care (spinal and joint mobilization)

Parameter	Typical range / notes
Setting	In-office
Approach	Instrumentation and/or manual adjusting
Adjunctive therapy	Myofascial release
Duration per session	10-15 minutes
Weekly frequency	2-3 times/week
Purpose	Improve proprioception and muscle feedback

Supplements (general guideline dosing)

Doses below are general guideline ranges and may vary based on medications, comorbidities, and lab findings. Use clinical guidance and monitoring.

Supplement	Why it may help	Typical daily dose (general)
Alpha-Lipoic Acid	Reduces nerve pain, supports blood flow, lowers inflammation	600 mg
Acetyl-L-Carnitine	Improves nerve repair, reduces pain, boosts energy production	1,500 mg
Methylcobalamin (B12)	Protects and repairs nerve fibers, reduces pain	1,500 mcg
Benfotiamine (B1)	Reduces nerve pain, improves nerve conduction, lowers inflammation	300-600 mg
Magnesium Glycinate	Calms nerve excitability, improves circulation, reduces pain signals	200-400 mg
Omega-3 Fatty Acids	Reduces inflammation, supports nerve membranes, reduces pain	1,000-4,000 mg

References

Joshua, A. M., & Misri, Z. (2022). Peripheral nerve disorders. In Physiotherapy for Adult Neurological Conditions (pp. 621-729). Singapore: Springer Nature Singapore.https://pubmed.ncbi.nlm.nih.gov/38633823/

Hicks, C. W., Wang, D., Windham, B. G., Matsushita, K., & Selvin, E. (2021). Prevalence of peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two US cohorts. Scientific Reports, 11(1), Article 19159. https://doi.org/10.1038/s41598-021-98565-w

Hammi C, Yeung B. Neuropathy [Internet]. StatPearls - NCBI Bookshelf. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542220/

Baskozos G, Hébert HL, Pascal MM, Themistocleous AC, Macfarlane GJ, Wynick D, Bennett DL, Smith BH. Epidemiology of neuropathic pain: an analysis of prevalence and associated factors in UK Biobank. Pain Rep. 2023 Mar;8(2):e1066 https://pubmed.ncbi.nlm.nih.gov/37090682/

Elafros, M. A., Kvalsund, M. P., & Callaghan, B. C. (2022). The global burden of polyneuropathy—In need of an accurate assessment. JAMA Neurology, 79(6), 537–538. https://doi.org/10.1001/jamaneurol.2022.0565

Foundation for Peripheral Neuropathy. (2022). The global burden of polyneuropathy. Retrieved from Foundation for Peripheral Neuropathy website on 02-26-26 https://www.foundationforpn.org/the-global-burden-of-polyneuropathy/?gad_source=1&gad_campaignid=16806624627&gbraid=0AAAACOazv2QJTRJoQ0bx8HEmrUDznuC3&gclid=CjwKCAiA-_MBhAKEiwASBmsBDEorh4ESsw6zQvNX5srJ0LUfExnF50_n1Ft6tWnMRzs-jEXdPJaaRoCgDcQAvD_BwE

Johnson, M. I., et al. (2022). A secondary analysis of the Meta-TENS study to improve pain management. Nih. 58(6), 803. https://doi.org/10.3390/jcm58060803

Wang, Q., et al. (2024). The effects of pulsed electromagnetic field therapy on knee osteoarthritis: A randomized controlled trial. Frontiers in Medicine, 11, 1435277. https://doi.org/10.3389/fmed.2024.1435277

Laforgia, M., Laface, C., Calabro, C., Ferraiuolo, S., Ungaro, V., Tricarico, D., ... & Ranieri, G. (2021). Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. International journal of molecular sciences, 22(4), 1980. https://pmc.ncbi.nlm.nih.gov/articles/PMC7922628/

Li L, Li T, Qu X, Sun G, Fu Q, Han G. Stress/cell death pathways, neuroinflammation and neuropathic pain. Immunological reviews. 2024 Jan;321(1):33-51. https://pubmed.ncbi.nlm.nih.gov/37688390/

Saleh DO, Sedik AA. Novel drugs affecting diabetic peripheral neuropathy. Iranian Journal of Basic Medical Sciences. 2024;27(6):657. https://pubmed.ncbi.nlm.nih.gov/38645500/

Dompe, C., Moncrieff, L., Matys, J., Grzech-Leśniak, K., Kocherova, I., Bryja, A., Bruska, M., Dominiak, M., Mozdziak, P., Skiba, T., Shibli, J., Volponi, A. A., Kempisty, B., & Dyszkiewicz-Konwińska, M. (2020). Photobiomodulation—Underlying mechanism and clinical applications. Journal of Clinical Medicine, 9(6), 1724. https://doi.org/10.3390/jcm9061724

Argenta, P. A., Ballman, K. V., Geller, M. A., Carson, L. F., Ghebre, R., Mullany, S. A., Teoh, D. G., Winterhoff, B. J., Rivard, C. L., & Erickson, B. K. (2016). The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. Gynecologic Oncology, 144(1), 159–166. https://doi.org/10.1016/j.ygyno.2016.11.013

Ebadi, S. A., Tabeie, F., Tavakoli, S., & Khalili, S. (2023). Effects of Photobiomodulation With Two Wavelengths of 630 and 810 nm on Diabetic Neuropathy. Journal of Lasers in Medical Sciences, 14, e22. https://doi.org/10.34172/jlms.2023.22

Korada, H. Y., Arora, E., Maiya, G. A., Rao, S., Hande, M., Shetty, S., Gundmi, S., Anche, P., & Amravadi, S. (2022). Effectiveness of photobiomodulation therapy on neuropathic pain, nerve conduction and plantar pressure distribution in diabetic peripheral neuropathy - a systematic review. Current Diabetes Reviews, 19(9). https://doi.org/10.2174/1573399818666220429085256

De Oliveira Rosso, M. P., Buchaim, D. V., Kawano, N., Furlanette, G., Pomini, K. T., & Buchaim, R. L. (2018). Photobiomodulation therapy (PBMT) in Peripheral Nerve Regeneration: A Systematic review. Bioengineering, 5(2), 44. https://doi.org/10.3390/bioengineering5020044

Guo, J., Hai, H., & Ma, Y. (2022). Application of extracorporeal shock wave therapy in nervous system diseases: A review. Frontiers in Neurology, 13. https://doi.org/10.3389/fneur.2022.963849

Kou, D., Chen, Q., Wang, Y., Xu, G., Lei, M., Tang, X., Ni, H., & Zhang, F. (2024). The application of extracorporeal shock wave therapy on stem cells therapy to treat various diseases. Stem Cell Research & Therapy, 15(1). https://doi.org/10.1186/s13287-024-03888-w

Chen, Y., Chen, K., Yin, T., Huang, T., Yuen, C., Chung, S., Sung, P., Tong, M., Chen, C., Chang, H., Lin, K., Ko, S., & Yip, H. (2015, December 15). Extracorporeal shock wave therapy effectively prevented diabetic neuropathy. https://pmc.ncbi.nlm.nih.gov/articles/PMC4731656

De La Corte-Rodríguez, H., Román-Belmonte, J. M., Rodríguez-Damiani, B. A., Vázquez-Sasot, A., & Rodríguez-Merchán, E. C. (2023). Extracorporeal shock wave therapy for the treatment of musculoskeletal pain: A Narrative review. Healthcare, 11(21), 2830. https://doi.org/10.3390/healthcare11212830

Yang, L., Li, X., Li, S., Yang, J., & Meng, D. (2024). Effect of extracorporeal shock wave therapy on nerve conduction: a systematic review and meta-analysis. Frontiers in Neurology, 15. https://doi.org/10.3389/fneur.2024.1493692

International Society for Medical Shockwave Treatment. (2024, January 3). ISMST guidelines for extracorporeal shock wave therapy (ESWT). https://shockwavetherapy.org/wp-content/uploads/2024/01/ISMST-Guidelines-for-ESWT-_-engl-20240103.pdf

Effect of extracorporeal shockwaves on diabetic neuropathic foot. (2020). International Journal of Pharmaceutical Research, 12(04). https://doi.org/10.31838/ijpr/2020.sp2.554

Jeong, D., Lee, J. H., Lee, G. B., Shin, K. H., Hwang, J., Jang, S. Y., Yoo, J., & Jang, W. Y. (2023). Application of extracorporeal shockwave therapy to improve microcirculation in diabetic foot ulcers: A prospective study. Medicine, 102(11), e33310. https://doi.org/10.1097/md.0000000000033310

Johnson, M. I., Paley, C. A., Jones, G., Mulvey, M. R., & Wittkopf, P. G. (2022). Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study). BMJ Open, 12(2), e051073. https://doi.org/10.1136/bmjopen-2021-051073

Tassone, E. E., Page, J. C., & Slepian, M. J. (2023). Assessing the effects of pulsed electromagnetic therapy on painful diabetic distal symmetric peripheral neuropathy: a Double-Blind randomized controlled trial. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968231190413

Williamson, T. K., Rodriguez, H. C., Gonzaba, A., Poddar, N., Norwood, S. M., & Gupta, A. (2021). H-Wave® Device stimulation: A critical review. Journal of Personalized Medicine, 11(11), 1134. https://doi.org/10.3390/jpm11111134

Blum, K., Chen, A. L., Chen, T. J., Prihoda, T. J., Schoolfield, J., DiNubile, N., Waite, R. L., Arcuri, V., Kerner, M., Braverman, E. R., Rhoades, P., & Tung, H. (2008). The H-Wave® device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. Advances in Therapy, 25(7), 644–657. https://doi.org/10.1007/s12325-008-0073-3

Johnson, M. I., Paley, C. A., Wittkopf, P. G., Mulvey, M. R., & Jones, G. (2022). Characterising the features of 381 clinical studies evaluating transcutaneous electrical nerve stimulation (TENS) for pain relief: A secondary analysis of the Meta-TENS Study to improve future research. Medicina, 58(6), 803. https://doi.org/10.3390/medicina58060803

Wolfe, D., Rosenstein, B., & Fortin, M. (2024). The effect of EMS, IFC and TENS on patient-reported outcome measures for chronic low back pain: a systematic review and meta-analysis. Frontiers in Pain Research, 5. https://doi.org/10.3389/fpain.2024.1346694

Vance, C. G. T., Dailey, D. L., Chimenti, R. L., Van Gorp, B. J., Crofford, L. J., & Sluka, K. A. (2022). Using TENS for pain control: Update on the state of the evidence. Medicina, 58(10), 1332. https://doi.org/10.3390/medicina58101332

Jamal, A., Ahmad, I., Ahamed, N., Azharuddin, M., Alam, F., & Hussain, M. E. (2019). Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: a randomized controlled trial. Journal of Diabetes & Metabolic Disorders, 19(1), 61–69. https://doi.org/10.1007/s40200-019-00476-1

Robinson, C. C., Barreto, R. P. G., & Della Méa Plentz, R. (2018, September 1). Effects of whole body vibration in individuals with diabetic peripheral neuropathy: a systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC6146195

Sabziparvar, M., Naghdi, S., Ansari, N. N., & Fateh, H. (2022). Implication of Local Plantar Vibration in Patients with Diabetic Neuropathy. Iranian Journal of Public Health. https://doi.org/10.18502/ijph.v51i8.10284

Krasnow, S. M., Rubin, C. T., Roeland, E. J., Horak, F. B., Stoyles, S. A., Dieckmann, N. F., Braun, K. N., & Winters-Stone, K. M. (2025). Low-Intensity vibration to reduce symptoms and improve physical functioning in cancer survivors with Chemotherapy-Induced peripheral neuropathy: a pilot randomized trial. JCO Oncology Practice. https://doi.org/10.1200/op-24-00961

Sohrabzadeh, E., Kalantari, K. K., Naimi, S. S., Daryabor, A., & Akbari, N. J. (2021). The immediate effect of a single whole-body vibration session on balance, skin sensation and pain in patients with type 2 diabetic neuropathy. Journal of Diabetes & Metabolic Disorders, 21(1), 43–49. https://doi.org/10.1007/s40200-021-00933-w

Kessler, N. J., Lockard, M. M., & Fischer, J. (2020). Whole body vibration improves symptoms of diabetic peripheral neuropathy. Journal of Bodywork and Movement Therapies, 24(2), 1–3. https://doi.org/10.1016/j.jbmt.2020.01.004

De Oliveira Marques, C., Espindula, I. A., Darko, E. K. K., Bonetti, L. V., Sonza, A., Partata, W. A., Faccioni-Heuser, M. C., & Malysz, T. (2021). Whole-body vibration therapy does not improve the peripheral nerve regeneration in experimental model. https://pmc.ncbi.nlm.nih.gov/articles/PMC8020024

Liu, Y. W., Liu, C. T., & Su, Y. L. (2020). A narrative review of complementary nutritional supplements for chemotherapy-induced peripheral neuropathy. Alternative Therapies in Health and Medicine, 26(4), 43-49. https://pubmed.ncbi.nlm.nih.gov/31634876/

Beltramo, E., Berrone, E., Tarallo, S., & Porta, M. (2008). Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta diabetologica, 45(3), 131-141. https://pubmed.ncbi.nlm.nih.gov/18581039/

Fraser, D. A., Diep, L. M., Hovden, I. A., Nilsen, K. B., Sveen, K. A., Seljeflot, I., & Hanssen, K. F. (2012). The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care, 35(5), 1095-1097. https://pubmed.ncbi.nlm.nih.gov/22446172/

Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., Hashemzade, S., Jafarabadi, M. A., Montazeri, V., Keshavarz, S. A., & Darabi, M. (2012). Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial. BMC Cancer, 12(1). https://doi.org/10.1186/1471-2407-12-355

Zhang, A. C., De Silva, M. E. H., MacIsaac, R. J., Roberts, L., Kamel, J., Craig, J. P., Busija, L., & Downie, L. E. (2019). Omega-3 polyunsaturated fatty acid oral supplements for improving peripheral nerve health: a systematic review and meta-analysis. Nutrition Reviews, 78(4), 323–341. https://doi.org/10.1093/nutrit/nuz054

Ziegler, D. (2023). Pathogenetic treatments for diabetic peripheral neuropathy. Diabetes Research and Clinical Practice, 206, 110764. https://pubmed.ncbi.nlm.nih.gov/38245327/

Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes care. 2006 Nov 1;29(11):2365-70. https://pubmed.ncbi.nlm.nih.gov/17065669/

Abdullah, N., Tieppo Francio, V., Falowski, S., Ibrahim, Y., Malinowski, M., Budwany, R., ... & Pritzlaff, S. (2024). A Systematic Guideline by the ASPN Workgroup on the Evidence, Education and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET. https://pubmed.ncbi.nlm.nih.gov/38633823/

Health Sciences Authority. (2023). High-dose vitamin B6 and risk of peripheral neuropathy. Retrieved from https://www.hsa.gov.sg/announcements/safety-alert/high-dose-vitamin-b6-and-risk-of-peripheral-neuropathy

Therapeutic Goods Administration. (2022). Health supplements containing vitamin B6 can cause peripheral neuropathy. Retrieved from https://www.tga.gov.au/news/safety-alerts/health-supplements-containing-vitamin-b6-can-cause-peripheral-neuropathy

Chiropractic, A. (2025, April 7). Case study: Treating peripheral neuropathy with Chiropractic care. Advantage Chiropractic. https://www.chiropractornewberlin.com/case-study-treating-neuropathy-with-chiropractic

Advantage Health Center. (2025, April 7). Case study: Relief from peripheral neuropathy with chiropractic care. Advantage Health. https://advantage-healthcenter.com/case-study-neuropathy-relief-eau-claire

Comparative efficacy of chiropractic adjustments in peripheral neuropathy management. (n.d.). https://www.backinactionbodyworks.com/blog/comparative-efficacy-of-chiropractic-adjustments-in-peripheral-neuropathy-management

Ramos, G., & Martin, W. (1994). Effects of vertebral axial decompression on intradiscal pressure. Journal of Neurosurgery, 81(3), 350–353. https://pubmed.ncbi.nlm.nih.gov/8057141/

Gose, E. E. et al. (1998). Vertebral axial decompression treatment for pain associated with herniated or degenerated discs or facet syndrome: An outcome study. Neurological Research, 20(4). https://pubmed.ncbi.nlm.nih.gov/9583577/

Naguszewski, W. K. et al. (2001). Dermatomal somatosensory evoked potential demonstration of nerve root decompression after VAX-D therapy. Neurological Research, 23(7). https://pubmed.ncbi.nlm.nih.gov/11680509/

McMillin, D. S., & Sherry, E. (2002). Sudden progression of lumbar disk protrusion during vertebral axial decompression traction therapy. Mayo Clinic Proceedings.

Aetna. (2025). Vertebral Axial Decompression [Clinical Policy Bulletin]. https://www.aetna.com/cpb/medical/data/100_199/0180.html

Beattie PF, Nelson RM, Michener LA, Cammarata J, Donley J. Outcomes after a prone lumbar traction protocol for patients with activity-limiting low back pain: a prospective case series study. Arch Phys Med Rehabil. 2008 Feb;89(2):269-74. doi: 10.1016/j.apmr.2007.06.778. PMID: 18226650. https://pubmed.ncbi.nlm.nih.gov/18226650/

Rotaru, A., TÂrtea, E. A., & IancĂu, M. (2020). Classical therapies versus combined therapies in diabetic neuropathy. PubMed, 46(2), 123–128. https://doi.org/10.12865/chsj.46.02.04

Vorobeychik, Y., Gordin, V., Mao, J., & Chen, L. (2011). Combination therapy for neuropathic pain. CNS Drugs, 25(12), 1023–1034. https://doi.org/10.2165/11596280-000000000-00000

Sherry E, Kitchener P, Smart R. A prospective randomized controlled study of VAX-D and TENS for the treatment of chronic low back pain. Neurol Res. 2001 Oct;23(7):780-4. doi: 10.1179/016164101101199180. PMID: 11680522. https://pubmed.ncbi.nlm.nih.gov/11680522/

Old Reference List (Original Order)

Each entry is labeled with its original position (Old #) and its new position after reordering (New #).

Old 1 (New 46): Abdullah, N., Tieppo Francio, V., Falowski, S., Ibrahim, Y., Malinowski, M., Budwany, R., ... & Pritzlaff, S. (2024). A Systematic Guideline by the ASPN Workgroup on the Evidence, Education and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET. https://pubmed.ncbi.nlm.nih.gov/38633823/

Old 2 (New 50): Advantage Health Center. (2025, April 7). Case study: Relief from peripheral neuropathy with chiropractic care. Advantage Health. https://advantage-healthcenter.com/case-study-neuropathy-relief-eau-claire

Old 3 (New 15): Argenta, P. A., Ballman, K. V., Geller, M. A., Carson, L. F., Ghebre, R., Mullany, S. A., Teoh, D. G., Winterhoff, B. J., Rivard, C. L., & Erickson, B. K. (2016). The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. Gynecologic Oncology, 144(1), 159–166. https://doi.org/10.1016/j.ygyno.2016.11.013

Old 4 (New 4): Baskozos, G., et al. (2023). Epidemiology of neuropathic pain: An analysis of prevalence. Pain Reports, 8(4), e1056. [Note: complete author list not specified; include as appropriate in final bibliography.

Old 5 (New 40): Beltramo, E., Berrone, E., Tarallo, S., & Porta, M. (2008). Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta diabetologica, 45(3), 131-141.

Old 6 (New 29): Blum, K., Chen, A. L., Chen, T. J., Prihoda, T. J., Schoolfield, J., DiNubile, N., Waite, R. L., Arcuri, V., Kerner, M., Braverman, E. R., Rhoades, P., & Tung, H. (2008). The H-Wave® device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. Advances in Therapy, 25(7), 644–657. https://doi.org/10.1007/s12325-008-0073-3

Old 7 (New 21): Chen, Y., Chen, K., Yin, T., Huang, T., Yuen, C., Chung, S., Sung, P., Tong, M., Chen, C., Chang, H., Lin, K., Ko, S., & Yip, H. (2015, December 15). Extracorporeal shock wave therapy effectively prevented diabetic neuropathy. https://pmc.ncbi.nlm.nih.gov/articles/PMC4731656

Old 8 (New 49): Chiropractic, A. (2025, April 7). Case study: Treating peripheral neuropathy with Chiropractic care. Advantage Chiropractic. https://www.chiropractornewberlin.com/case-study-treating-neuropathy-with-chiropractic

Old 9 (New 51): Comparative efficacy of chiropractic adjustments in peripheral neuropathy management. (n.d.). https://www.backinactionbodyworks.com/blog/comparative-efficacy-of-chiropractic-adjustments-in-peripheral-neuropathy-management

Old 10 (New 22): De La Corte-Rodríguez, H., Román-Belmonte, J. M., Rodríguez-Damiani, B. A., Vázquez-Sasot, A., & Rodríguez-Merchán, E. C. (2023). Extracorporeal shock wave therapy for the treatment of musculoskeletal pain: A Narrative review. Healthcare, 11(21), 2830. https://doi.org/10.3390/healthcare11212830

Old 11 (New 38): De Oliveira Marques, C., Espindula, I. A., Darko, E. K. K., Bonetti, L. V., Sonza, A., Partata, W. A., Faccioni-Heuser, M. C., & Malysz, T. (2021). Whole-body vibration therapy does not improve the peripheral nerve regeneration in experimental model. https://pmc.ncbi.nlm.nih.gov/articles/PMC8020024

Old 12 (New 18): De Oliveira Rosso, M. P., Buchaim, D. V., Kawano, N., Furlanette, G., Pomini, K. T., & Buchaim, R. L. (2018). Photobiomodulation therapy (PBMT) in Peripheral Nerve Regeneration: A Systematic review. Bioengineering, 5(2), 44. https://doi.org/10.3390/bioengineering5020044

Old 13 (New 14): Dompe, C., Moncrieff, L., Matys, J., Grzech-Leśniak, K., Kocherova, I., Bryja, A., Bruska, M., Dominiak, M., Mozdziak, P., Skiba, T., Shibli, J., Volponi, A. A., Kempisty, B., & Dyszkiewicz-Konwińska, M. (2020). Photobiomodulation—Underlying mechanism and clinical applications. Journal of Clinical Medicine, 9(6), 1724. https://doi.org/10.3390/jcm9061724

Old 14 (New 16): Ebadi, S. A., Tabeie, F., Tavakoli, S., & Khalili, S. (2023). Effects of Photobiomodulation With Two Wavelengths of 630 and 810 nm on Diabetic Neuropathy. Journal of Lasers in Medical Sciences, 14, e22. https://doi.org/10.34172/jlms.2023.22

Old 15 (New 25): Effect of extracorporeal shockwaves on diabetic neuropathic foot. (2020). International Journal of Pharmaceutical Research, 12(04). https://doi.org/10.31838/ijpr/2020.sp2.554

Old 16 (New 5): Elafros, M. A., Kvalsund, M. P., & Callaghan, B. C. (2022). The global burden of polyneuropathy—In need of an accurate assessment. JAMA Neurology, 79(6), 537–538. https://doi.org/10.1001/jamaneurol.2022.0565

Old 17 (New 6): Foundation for Peripheral Neuropathy. (2025). The global burden of polyneuropathy. Retrieved from Foundation for Peripheral Neuropathy website.

Old 18 (New 41): Fraser, D. A., Diep, L. M., Hovden, I. A., Nilsen, K. B., Sveen, K. A., Seljeflot, I., & Hanssen, K. F. (2012). The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care, 35(5), 1095-1097.

Old 19 (New 42): Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., Hashemzade, S., Jafarabadi, M. A., Montazeri, V., Keshavarz, S. A., & Darabi, M. (2012). Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial. BMC Cancer, 12(1). https://doi.org/10.1186/1471-2407-12-355

Old 20 (New 19): Guo, J., Hai, H., & Ma, Y. (2022). Application of extracorporeal shock wave therapy in nervous system diseases: A review. Frontiers in Neurology, 13. https://doi.org/10.3389/fneur.2022.963849

Old 21 (New 3): Hammi C, Yeung B. Neuropathy [Internet]. StatPearls - NCBI Bookshelf. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542220/

Old 22 (New 47): Health Sciences Authority. (2023). High-dose vitamin B6 and risk of peripheral neuropathy. Retrieved from https://www.hsa.gov.sg/announcements/safety-alert/high-dose-vitamin-b6-and-risk-of-peripheral-neuropathy

Old 23 (New 2): Hicks, C. W., Wang, D., Windham, B. G., Matsushita, K., & Selvin, E. (2021). Prevalence of peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two US cohorts. Scientific Reports, 11(1), Article 19159. https://doi.org/10.1038/s41598-021-98565-w

Old 24 (New 24): International Society for Medical Shockwave Treatment. (2024, January 3). ISMST guidelines for extracorporeal shock wave therapy (ESWT). https://shockwavetherapy.org/wp-content/uploads/2024/01/ISMST-Guidelines-for-ESWT-_-engl-20240103.pdf

Old 25 (New 32): Jamal, A., Ahmad, I., Ahamed, N., Azharuddin, M., Alam, F., & Hussain, M. E. (2019). Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: a randomized controlled trial. Journal of Diabetes & Metabolic Disorders, 19(1), 61–69. https://doi.org/10.1007/s40200-019-00476-1

Old 26 (New 26): Jeong, D., Lee, J. H., Lee, G. B., Shin, K. H., Hwang, J., Jang, S. Y., Yoo, J., & Jang, W. Y. (2023). Application of extracorporeal shockwave therapy to improve microcirculation in diabetic foot ulcers: A prospective study. Medicine, 102(11), e33310. https://doi.org/10.1097/md.0000000000033310

Old 27 (New 7): Johnson, M. I., et al. (2022). A secondary analysis of the Meta-TENS study to improve pain management. Nih. 58(6), 803. https://doi.org/10.3390/jcm58060803

Old 28 (New 8): Johnson, M. I., Paley, C. A., Jones, G., Mulvey, M. R., & Wittkopf, P. G. (2022). Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study). BMJ Open, 12(2), e051073. https://doi.org/10.1136/bmjopen-2021-051073

Old 29 (New 9): Johnson, M. I., Paley, C. A., Wittkopf, P. G., Mulvey, M. R., & Jones, G. (2022). Characterising the features of 381 clinical studies evaluating transcutaneous electrical nerve stimulation (TENS) for pain relief: A secondary analysis of the Meta-TENS Study to improve future research. Medicina, 58(6), 803. https://doi.org/10.3390/medicina58060803

Old 30 (New 1): Joshua, A. M., & Misri, Z. (2022). Peripheral nerve disorders. In Physiotherapy for Adult Neurological Conditions (pp. 621-729). Singapore: Springer Nature Singapore.

Old 31 (New 37): Kessler, N. J., Lockard, M. M., & Fischer, J. (2020). Whole body vibration improves symptoms of diabetic peripheral neuropathy. Journal of Bodywork and Movement Therapies, 24(2), 1–3. https://doi.org/10.1016/j.jbmt.2020.01.004

Old 32 (New 17): Korada, H. Y., Arora, E., Maiya, G. A., Rao, S., Hande, M., Shetty, S., Gundmi, S., Anche, P., & Amravadi, S. (2022). Effectiveness of photobiomodulation therapy on neuropathic pain, nerve conduction and plantar pressure distribution in diabetic peripheral neuropathy - a systematic review. Current Diabetes Reviews, 19(9). https://doi.org/10.2174/1573399818666220429085256

Old 33 (New 20): Kou, D., Chen, Q., Wang, Y., Xu, G., Lei, M., Tang, X., Ni, H., & Zhang, F. (2024). The application of extracorporeal shock wave therapy on stem cells therapy to treat various diseases. Stem Cell Research & Therapy, 15(1). https://doi.org/10.1186/s13287-024-03888-w

Old 34 (New 35): Krasnow, S. M., Rubin, C. T., Roeland, E. J., Horak, F. B., Stoyles, S. A., Dieckmann, N. F., Braun, K. N., & Winters-Stone, K. M. (2025). Low-Intensity vibration to reduce symptoms and improve physical functioning in cancer survivors with Chemotherapy-Induced peripheral neuropathy: a pilot randomized trial. JCO Oncology Practice. https://doi.org/10.1200/op-24-00961

Old 35 (New 11): Laforgia, M., Laface, C., Calabro, C., Ferraiuolo, S., Ungaro, V., Tricarico, D., ... & Ranieri, G. (2021). Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. International journal of molecular sciences, 22(4), 1980.

Old 36 (New 12): Li L, Li T, Qu X, Sun G, Fu Q, Han G. Stress/cell death pathways, neuroinflammation and neuropathic pain. Immunological reviews. 2024 Jan;321(1):33-51.

Old 37 (New 39): Liu, Y. W., Liu, C. T., & Su, Y. L. (2020). A narrative review of complementary nutritional supplements for chemotherapy-induced peripheral neuropathy. Alternative Therapies in Health and Medicine, 26(4), 43-49.

Old 38 (New 33): Robinson, C. C., Barreto, R. P. G., & Della Méa Plentz, R. (2018, September 1). Effects of whole body vibration in individuals with diabetic peripheral neuropathy: a systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC6146195

Old 39 (New 57): Rotaru, A., TÂrtea, E. A., & IancĂu, M. (2020). Classical therapies versus combined therapies in diabetic neuropathy. PubMed, 46(2), 123–128. https://doi.org/10.12865/chsj.46.02.04

Old 40 (New 34): Sabziparvar, M., Naghdi, S., Ansari, N. N., & Fateh, H. (2022). Implication of Local Plantar Vibration in Patients with Diabetic Neuropathy. Iranian Journal of Public Health. https://doi.org/10.18502/ijph.v51i8.10284

Old 41 (New 13): Saleh DO, Sedik AA. Novel drugs affecting diabetic peripheral neuropathy. Iranian Journal of Basic Medical Sciences. 2024;27(6):657.

Old 42 (New 36): Sohrabzadeh, E., Kalantari, K. K., Naimi, S. S., Daryabor, A., & Akbari, N. J. (2021). The immediate effect of a single whole-body vibration session on balance, skin sensation and pain in patients with type 2 diabetic neuropathy. Journal of Diabetes & Metabolic Disorders, 21(1), 43–49. https://doi.org/10.1007/s40200-021-00933-w

Old 43 (New 27): Tassone, E. E., Page, J. C., & Slepian, M. J. (2023). Assessing the effects of pulsed electromagnetic therapy on painful diabetic distal symmetric peripheral neuropathy: a Double-Blind randomized controlled trial. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968231190413

Old 44 (New 48): Therapeutic Goods Administration. (2022). Health supplements containing vitamin B6 can cause peripheral neuropathy. Retrieved from https://www.tga.gov.au/news/safety-alerts/health-supplements-containing-vitamin-b6-can-cause-peripheral-neuropathy

Old 45 (New 31): Vance, C. G. T., Dailey, D. L., Chimenti, R. L., Van Gorp, B. J., Crofford, L. J., & Sluka, K. A. (2022). Using TENS for pain control: Update on the state of the evidence. Medicina, 58(10), 1332. https://doi.org/10.3390/medicina58101332

Old 46 (New 58): Vorobeychik, Y., Gordin, V., Mao, J., & Chen, L. (2011). Combination therapy for neuropathic pain. CNS Drugs, 25(12), 1023–1034. https://doi.org/10.2165/11596280-000000000-00000

Old 47 (New 10): Wang, Q., et al. (2024). The effects of pulsed electromagnetic field therapy on knee osteoarthritis: A randomized controlled trial. Frontiers in Medicine, 11, 1435277. https://doi.org/10.3389/fmed.2024.1435277

Old 48 (New 28): Williamson, T. K., Rodriguez, H. C., Gonzaba, A., Poddar, N., Norwood, S. M., & Gupta, A. (2021). H-Wave® Device stimulation: A critical review. Journal of Personalized Medicine, 11(11), 1134. https://doi.org/10.3390/jpm11111134

Old 49 (New 30): Wolfe, D., Rosenstein, B., & Fortin, M. (2024). The effect of EMS, IFC and TENS on patient-reported outcome measures for chronic low back pain: a systematic review and meta-analysis. Frontiers in Pain Research, 5. https://doi.org/10.3389/fpain.2024.1346694

Old 50 (New 23): Yang, L., Li, X., Li, S., Yang, J., & Meng, D. (2024). Effect of extracorporeal shock wave therapy on nerve conduction: a systematic review and meta-analysis. Frontiers in Neurology, 15. https://doi.org/10.3389/fneur.2024.1493692

Old 51 (New 43): Zhang, A. C., De Silva, M. E. H., MacIsaac, R. J., Roberts, L., Kamel, J., Craig, J. P., Busija, L., & Downie, L. E. (2019). Omega-3 polyunsaturated fatty acid oral supplements for improving peripheral nerve health: a systematic review and meta-analysis. Nutrition Reviews, 78(4), 323–341. https://doi.org/10.1093/nutrit/nuz054

Old 52 (New 45): Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes care. 2006 Nov 1;29(11):2365-70.

Old 53 (New 44): Ziegler, D. (2023). Pathogenetic treatments for diabetic peripheral neuropathy. Diabetes Research and Clinical Practice, 206, 110764.

Old 54 (New 52): Ramos, G., & Martin, W. (1994). Effects of vertebral axial decompression on intradiscal pressure. Journal of Neurosurgery, 81(3), 350–353.

Old 55 (New 53): Gose, E. E. et al. (1998). Vertebral axial decompression treatment for pain associated with herniated or degenerated discs or facet syndrome: An outcome study. Neurological Research, 20(4).

Old 56 (New 59): Sherry E, Kitchener P, Smart R. A prospective randomized controlled study of VAX-D and TENS for the treatment of chronic low back pain. Neurol Res. 2001 Oct;23(7):780-4. doi: 10.1179/016164101101199180. PMID: 11680522.

Old 57 (New 54): Naguszewski, W. K. et al. (2001). Dermatomal somatosensory evoked potential demonstration of nerve root decompression after VAX-D therapy. Neurological Research, 23(7).

Old 58 (New 55): McMillin, D. S., & Sherry, E. (2002). Sudden progression of lumbar disk protrusion during vertebral axial decompression traction therapy. Mayo Clinic Proceedings.

Old 59 (New 56): Aetna. (2025). Vertebral Axial Decompression [Clinical Policy Bulletin].

New Reference List (Citation Order)

Each entry is labeled with its new position (New #) and its original position (Old #).

Note: “Pollock et al., 2022” is cited in the body but no matching reference entry was found in the original reference list, so it could not be placed in citation order.

New 1 (Old 30): Joshua, A. M., & Misri, Z. (2022). Peripheral nerve disorders. In Physiotherapy for Adult Neurological Conditions (pp. 621-729). Singapore: Springer Nature Singapore.

New 2 (Old 23): Hicks, C. W., Wang, D., Windham, B. G., Matsushita, K., & Selvin, E. (2021). Prevalence of peripheral neuropathy defined by monofilament insensitivity in middle-aged and older adults in two US cohorts. Scientific Reports, 11(1), Article 19159. https://doi.org/10.1038/s41598-021-98565-w

New 3 (Old 21): Hammi C, Yeung B. Neuropathy [Internet]. StatPearls - NCBI Bookshelf. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542220/

New 4 (Old 4): Baskozos, G., et al. (2023). Epidemiology of neuropathic pain: An analysis of prevalence. Pain Reports, 8(4), e1056. [Note: complete author list not specified; include as appropriate in final bibliography.

New 5 (Old 16): Elafros, M. A., Kvalsund, M. P., & Callaghan, B. C. (2022). The global burden of polyneuropathy—In need of an accurate assessment. JAMA Neurology, 79(6), 537–538. https://doi.org/10.1001/jamaneurol.2022.0565

New 6 (Old 17): Foundation for Peripheral Neuropathy. (2025). The global burden of polyneuropathy. Retrieved from Foundation for Peripheral Neuropathy website.

New 7 (Old 27): Johnson, M. I., et al. (2022). A secondary analysis of the Meta-TENS study to improve pain management. Nih. 58(6), 803. https://doi.org/10.3390/jcm58060803

New 8 (Old 28): Johnson, M. I., Paley, C. A., Jones, G., Mulvey, M. R., & Wittkopf, P. G. (2022). Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study). BMJ Open, 12(2), e051073. https://doi.org/10.1136/bmjopen-2021-051073

New 9 (Old 29): Johnson, M. I., Paley, C. A., Wittkopf, P. G., Mulvey, M. R., & Jones, G. (2022). Characterising the features of 381 clinical studies evaluating transcutaneous electrical nerve stimulation (TENS) for pain relief: A secondary analysis of the Meta-TENS Study to improve future research. Medicina, 58(6), 803. https://doi.org/10.3390/medicina58060803

New 10 (Old 47): Wang, Q., et al. (2024). The effects of pulsed electromagnetic field therapy on knee osteoarthritis: A randomized controlled trial. Frontiers in Medicine, 11, 1435277. https://doi.org/10.3389/fmed.2024.1435277

New 11 (Old 35): Laforgia, M., Laface, C., Calabro, C., Ferraiuolo, S., Ungaro, V., Tricarico, D., ... & Ranieri, G. (2021). Peripheral neuropathy under oncologic therapies: a literature review on pathogenetic mechanisms. International journal of molecular sciences, 22(4), 1980.

New 12 (Old 36): Li L, Li T, Qu X, Sun G, Fu Q, Han G. Stress/cell death pathways, neuroinflammation and neuropathic pain. Immunological reviews. 2024 Jan;321(1):33-51.

New 13 (Old 41): Saleh DO, Sedik AA. Novel drugs affecting diabetic peripheral neuropathy. Iranian Journal of Basic Medical Sciences. 2024;27(6):657.

New 14 (Old 13): Dompe, C., Moncrieff, L., Matys, J., Grzech-Leśniak, K., Kocherova, I., Bryja, A., Bruska, M., Dominiak, M., Mozdziak, P., Skiba, T., Shibli, J., Volponi, A. A., Kempisty, B., & Dyszkiewicz-Konwińska, M. (2020). Photobiomodulation—Underlying mechanism and clinical applications. Journal of Clinical Medicine, 9(6), 1724. https://doi.org/10.3390/jcm9061724

New 15 (Old 3): Argenta, P. A., Ballman, K. V., Geller, M. A., Carson, L. F., Ghebre, R., Mullany, S. A., Teoh, D. G., Winterhoff, B. J., Rivard, C. L., & Erickson, B. K. (2016). The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. Gynecologic Oncology, 144(1), 159–166. https://doi.org/10.1016/j.ygyno.2016.11.013

New 16 (Old 14): Ebadi, S. A., Tabeie, F., Tavakoli, S., & Khalili, S. (2023). Effects of Photobiomodulation With Two Wavelengths of 630 and 810 nm on Diabetic Neuropathy. Journal of Lasers in Medical Sciences, 14, e22. https://doi.org/10.34172/jlms.2023.22

New 17 (Old 32): Korada, H. Y., Arora, E., Maiya, G. A., Rao, S., Hande, M., Shetty, S., Gundmi, S., Anche, P., & Amravadi, S. (2022). Effectiveness of photobiomodulation therapy on neuropathic pain, nerve conduction and plantar pressure distribution in diabetic peripheral neuropathy - a systematic review. Current Diabetes Reviews, 19(9). https://doi.org/10.2174/1573399818666220429085256

New 18 (Old 12): De Oliveira Rosso, M. P., Buchaim, D. V., Kawano, N., Furlanette, G., Pomini, K. T., & Buchaim, R. L. (2018). Photobiomodulation therapy (PBMT) in Peripheral Nerve Regeneration: A Systematic review. Bioengineering, 5(2), 44. https://doi.org/10.3390/bioengineering5020044

New 19 (Old 20): Guo, J., Hai, H., & Ma, Y. (2022). Application of extracorporeal shock wave therapy in nervous system diseases: A review. Frontiers in Neurology, 13. https://doi.org/10.3389/fneur.2022.963849

New 20 (Old 33): Kou, D., Chen, Q., Wang, Y., Xu, G., Lei, M., Tang, X., Ni, H., & Zhang, F. (2024). The application of extracorporeal shock wave therapy on stem cells therapy to treat various diseases. Stem Cell Research & Therapy, 15(1). https://doi.org/10.1186/s13287-024-03888-w

New 21 (Old 7): Chen, Y., Chen, K., Yin, T., Huang, T., Yuen, C., Chung, S., Sung, P., Tong, M., Chen, C., Chang, H., Lin, K., Ko, S., & Yip, H. (2015, December 15). Extracorporeal shock wave therapy effectively prevented diabetic neuropathy. https://pmc.ncbi.nlm.nih.gov/articles/PMC4731656

New 22 (Old 10): De La Corte-Rodríguez, H., Román-Belmonte, J. M., Rodríguez-Damiani, B. A., Vázquez-Sasot, A., & Rodríguez-Merchán, E. C. (2023). Extracorporeal shock wave therapy for the treatment of musculoskeletal pain: A Narrative review. Healthcare, 11(21), 2830. https://doi.org/10.3390/healthcare11212830

New 23 (Old 50): Yang, L., Li, X., Li, S., Yang, J., & Meng, D. (2024). Effect of extracorporeal shock wave therapy on nerve conduction: a systematic review and meta-analysis. Frontiers in Neurology, 15. https://doi.org/10.3389/fneur.2024.1493692

New 24 (Old 24): International Society for Medical Shockwave Treatment. (2024, January 3). ISMST guidelines for extracorporeal shock wave therapy (ESWT). https://shockwavetherapy.org/wp-content/uploads/2024/01/ISMST-Guidelines-for-ESWT-_-engl-20240103.pdf

New 25 (Old 15): Effect of extracorporeal shockwaves on diabetic neuropathic foot. (2020). International Journal of Pharmaceutical Research, 12(04). https://doi.org/10.31838/ijpr/2020.sp2.554

New 26 (Old 26): Jeong, D., Lee, J. H., Lee, G. B., Shin, K. H., Hwang, J., Jang, S. Y., Yoo, J., & Jang, W. Y. (2023). Application of extracorporeal shockwave therapy to improve microcirculation in diabetic foot ulcers: A prospective study. Medicine, 102(11), e33310. https://doi.org/10.1097/md.0000000000033310

New 27 (Old 43): Tassone, E. E., Page, J. C., & Slepian, M. J. (2023). Assessing the effects of pulsed electromagnetic therapy on painful diabetic distal symmetric peripheral neuropathy: a Double-Blind randomized controlled trial. Journal of Diabetes Science and Technology. https://doi.org/10.1177/19322968231190413

New 28 (Old 48): Williamson, T. K., Rodriguez, H. C., Gonzaba, A., Poddar, N., Norwood, S. M., & Gupta, A. (2021). H-Wave® Device stimulation: A critical review. Journal of Personalized Medicine, 11(11), 1134. https://doi.org/10.3390/jpm11111134

New 29 (Old 6): Blum, K., Chen, A. L., Chen, T. J., Prihoda, T. J., Schoolfield, J., DiNubile, N., Waite, R. L., Arcuri, V., Kerner, M., Braverman, E. R., Rhoades, P., & Tung, H. (2008). The H-Wave® device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. Advances in Therapy, 25(7), 644–657. https://doi.org/10.1007/s12325-008-0073-3

New 30 (Old 49): Wolfe, D., Rosenstein, B., & Fortin, M. (2024). The effect of EMS, IFC and TENS on patient-reported outcome measures for chronic low back pain: a systematic review and meta-analysis. Frontiers in Pain Research, 5. https://doi.org/10.3389/fpain.2024.1346694

New 31 (Old 45): Vance, C. G. T., Dailey, D. L., Chimenti, R. L., Van Gorp, B. J., Crofford, L. J., & Sluka, K. A. (2022). Using TENS for pain control: Update on the state of the evidence. Medicina, 58(10), 1332. https://doi.org/10.3390/medicina58101332

New 32 (Old 25): Jamal, A., Ahmad, I., Ahamed, N., Azharuddin, M., Alam, F., & Hussain, M. E. (2019). Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: a randomized controlled trial. Journal of Diabetes & Metabolic Disorders, 19(1), 61–69. https://doi.org/10.1007/s40200-019-00476-1

New 33 (Old 38): Robinson, C. C., Barreto, R. P. G., & Della Méa Plentz, R. (2018, September 1). Effects of whole body vibration in individuals with diabetic peripheral neuropathy: a systematic review. https://pmc.ncbi.nlm.nih.gov/articles/PMC6146195

New 34 (Old 40): Sabziparvar, M., Naghdi, S., Ansari, N. N., & Fateh, H. (2022). Implication of Local Plantar Vibration in Patients with Diabetic Neuropathy. Iranian Journal of Public Health. https://doi.org/10.18502/ijph.v51i8.10284

New 35 (Old 34): Krasnow, S. M., Rubin, C. T., Roeland, E. J., Horak, F. B., Stoyles, S. A., Dieckmann, N. F., Braun, K. N., & Winters-Stone, K. M. (2025). Low-Intensity vibration to reduce symptoms and improve physical functioning in cancer survivors with Chemotherapy-Induced peripheral neuropathy: a pilot randomized trial. JCO Oncology Practice. https://doi.org/10.1200/op-24-00961

New 36 (Old 42): Sohrabzadeh, E., Kalantari, K. K., Naimi, S. S., Daryabor, A., & Akbari, N. J. (2021). The immediate effect of a single whole-body vibration session on balance, skin sensation and pain in patients with type 2 diabetic neuropathy. Journal of Diabetes & Metabolic Disorders, 21(1), 43–49. https://doi.org/10.1007/s40200-021-00933-w

New 37 (Old 31): Kessler, N. J., Lockard, M. M., & Fischer, J. (2020). Whole body vibration improves symptoms of diabetic peripheral neuropathy. Journal of Bodywork and Movement Therapies, 24(2), 1–3. https://doi.org/10.1016/j.jbmt.2020.01.004

New 38 (Old 11): De Oliveira Marques, C., Espindula, I. A., Darko, E. K. K., Bonetti, L. V., Sonza, A., Partata, W. A., Faccioni-Heuser, M. C., & Malysz, T. (2021). Whole-body vibration therapy does not improve the peripheral nerve regeneration in experimental model. https://pmc.ncbi.nlm.nih.gov/articles/PMC8020024

New 39 (Old 37): Liu, Y. W., Liu, C. T., & Su, Y. L. (2020). A narrative review of complementary nutritional supplements for chemotherapy-induced peripheral neuropathy. Alternative Therapies in Health and Medicine, 26(4), 43-49.

New 40 (Old 5): Beltramo, E., Berrone, E., Tarallo, S., & Porta, M. (2008). Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta diabetologica, 45(3), 131-141.

New 41 (Old 18): Fraser, D. A., Diep, L. M., Hovden, I. A., Nilsen, K. B., Sveen, K. A., Seljeflot, I., & Hanssen, K. F. (2012). The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care, 35(5), 1095-1097.

New 42 (Old 19): Ghoreishi, Z., Esfahani, A., Djazayeri, A., Djalali, M., Golestan, B., Ayromlou, H., Hashemzade, S., Jafarabadi, M. A., Montazeri, V., Keshavarz, S. A., & Darabi, M. (2012). Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: A randomized double-blind placebo controlled trial. BMC Cancer, 12(1). https://doi.org/10.1186/1471-2407-12-355

New 43 (Old 51): Zhang, A. C., De Silva, M. E. H., MacIsaac, R. J., Roberts, L., Kamel, J., Craig, J. P., Busija, L., & Downie, L. E. (2019). Omega-3 polyunsaturated fatty acid oral supplements for improving peripheral nerve health: a systematic review and meta-analysis. Nutrition Reviews, 78(4), 323–341. https://doi.org/10.1093/nutrit/nuz054

New 44 (Old 53): Ziegler, D. (2023). Pathogenetic treatments for diabetic peripheral neuropathy. Diabetes Research and Clinical Practice, 206, 110764.

New 45 (Old 52): Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J. Oral treatment with α-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes care. 2006 Nov 1;29(11):2365-70.

New 46 (Old 1): Abdullah, N., Tieppo Francio, V., Falowski, S., Ibrahim, Y., Malinowski, M., Budwany, R., ... & Pritzlaff, S. (2024). A Systematic Guideline by the ASPN Workgroup on the Evidence, Education and Treatment Algorithm for Painful Diabetic Neuropathy: SWEET. https://pubmed.ncbi.nlm.nih.gov/38633823/

New 47 (Old 22): Health Sciences Authority. (2023). High-dose vitamin B6 and risk of peripheral neuropathy. Retrieved from https://www.hsa.gov.sg/announcements/safety-alert/high-dose-vitamin-b6-and-risk-of-peripheral-neuropathy

New 48 (Old 44): Therapeutic Goods Administration. (2022). Health supplements containing vitamin B6 can cause peripheral neuropathy. Retrieved from https://www.tga.gov.au/news/safety-alerts/health-supplements-containing-vitamin-b6-can-cause-peripheral-neuropathy

New 49 (Old 8): Chiropractic, A. (2025, April 7). Case study: Treating peripheral neuropathy with Chiropractic care. Advantage Chiropractic. https://www.chiropractornewberlin.com/case-study-treating-neuropathy-with-chiropractic

New 50 (Old 2): Advantage Health Center. (2025, April 7). Case study: Relief from peripheral neuropathy with chiropractic care. Advantage Health. https://advantage-healthcenter.com/case-study-neuropathy-relief-eau-claire

New 51 (Old 9): Comparative efficacy of chiropractic adjustments in peripheral neuropathy management. (n.d.). https://www.backinactionbodyworks.com/blog/comparative-efficacy-of-chiropractic-adjustments-in-peripheral-neuropathy-management

New 52 (Old 54): Ramos, G., & Martin, W. (1994). Effects of vertebral axial decompression on intradiscal pressure. Journal of Neurosurgery, 81(3), 350–353.

New 53 (Old 55): Gose, E. E. et al. (1998). Vertebral axial decompression treatment for pain associated with herniated or degenerated discs or facet syndrome: An outcome study. Neurological Research, 20(4).

New 54 (Old 57): Naguszewski, W. K. et al. (2001). Dermatomal somatosensory evoked potential demonstration of nerve root decompression after VAX-D therapy. Neurological Research, 23(7).

New 55 (Old 58): McMillin, D. S., & Sherry, E. (2002). Sudden progression of lumbar disk protrusion during vertebral axial decompression traction therapy. Mayo Clinic Proceedings.

New 56 (Old 59): Aetna. (2025). Vertebral Axial Decompression [Clinical Policy Bulletin].

New 57 (Old 39): Rotaru, A., TÂrtea, E. A., & IancĂu, M. (2020). Classical therapies versus combined therapies in diabetic neuropathy. PubMed, 46(2), 123–128. https://doi.org/10.12865/chsj.46.02.04

New 58 (Old 46): Vorobeychik, Y., Gordin, V., Mao, J., & Chen, L. (2011). Combination therapy for neuropathic pain. CNS Drugs, 25(12), 1023–1034. https://doi.org/10.2165/11596280-000000000-00000

New 59 (Old 56): Sherry E, Kitchener P, Smart R. A prospective randomized controlled study of VAX-D and TENS for the treatment of chronic low back pain. Neurol Res. 2001 Oct;23(7):780-4. doi: 10.1179/016164101101199180. PMID: 11680522.